Urological Research

, Volume 25, Issue 4, pp 223–230

Progress of fundamental research in Wilms' tumor

  • J. G. Wen
  • G. J. van Steenbrugge
  • R. M. Egeler
  • R. M. Nijman
Original Paper

DOI: 10.1007/BF00942090

Cite this article as:
Wen, J.G., van Steenbrugge, G.J., Egeler, R.M. et al. Urol. Res. (1997) 25: 223. doi:10.1007/BF00942090

Abstract

The progress of fundamental research on the histopathological and molecular genetic properties, model systems, growth factor involvement, and tumor markers of clinical nephroblastoma (Wilms' tumor) are reviewed. Histologically, Wilms' tumor (WT) has been found to reveal a disorganized renal developmental process in which blastema and epithelia are randomly interspersed in varying amounts of stroma. Anaplasia is the only criterion for assigning a WT as having an “unfavorable histology.” Cytogenetic analysis identified WT genes at chromosome 11p13 (WTI), 11p15 region (WT2), and 16q (WT3). Permanent in vitro WT cell lines and in vivo WT models, such as human xenografts, have been established which provide indefinite sources of tumor material for fundamental, as well as therapy-directed, research. Abnormalities of growth factor (GF) expression in WT indicate that GF may play an important role in WT pathogenesis. A series of monoclonal antibodies was tested in WT by immunohistochemical techniques to identify specific diagnostic and prognostic markers. p53 expression in anaplastic WT is significantly higher than in differentiated WTs, indicating p53 may be a prognostic marker. Although significant progress has been made in the fundamental research, our basic knowledge of this malignancy is still limited. The availability of suitable experimental models, particularly the human xenograft system, offers the opportunity for further study of the cell biological and molecular aspects of WT and its clinical progression.

Key words

Wilms' tumorHistopathology Experimental modelTumor markersGrowth factors

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. G. Wen
    • 1
  • G. J. van Steenbrugge
    • 1
  • R. M. Egeler
    • 2
  • R. M. Nijman
    • 3
  1. 1.Division of Urological Oncology, Medical FacultyErasmus University RotterdamRotterdamThe Netherlands
  2. 2.Department of Pediatric OncologySophia Children's HospitalRotterdamThe Netherlands
  3. 3.Department of Pediatric UrologyInstitute of Urology, Erasmus University and Sophia Children's Hospital RotterdamThe Netherlands